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Abstract
Background: Balanced anaesthesia with propofol and remifentanil, compared to sufentanil, often decreases mean
arterial pressure (MAP), heart rate (HR) and cardiac index (CI), raising concerns on tissue-oxygenation. This distinct
haemodynamic suppression might be attenuated by atropine. This double blinded RCT, investigates if induction
with propofol-sufentanil results in higher CI and tissue-oxygenation than with propofol-remifentanil and if atropine
has more pronounced beneficial effects on CI and tissue-oxygenation in a remifentanil-based anaesthesia.
Methods: In seventy patients scheduled for coronary bypass grafting (CABG), anaesthesia was induced and
maintained with propofol target controlled infusion (TCI) with a target effect-site concentration (Cet) of 2.0 μgml− 1
and either sufentanil (TCI Cet 0.48 ng ml− 1) or remifentanil (TCI Cet 8 ng ml− 1). If HR dropped below 60 bpm,
methylatropine (1 mg) was administered intravenously. Relative changes (Δ) in MAP, HR, stroke volume (SV), CI and
cerebral (SctO2) and peripheral (SptO2) tissue-oxygenation during induction of anaesthesia and after atropine
administration were analysed.
Results: The sufentanil group compared to the remifentanil group showed significantly less decrease in MAP (Δ =
− 23 ± 13 vs. -36 ± 13 mmHg), HR (Δ = − 5 ± 7 vs. -10 ± 10 bpm), SV (Δ = − 23 ± 18 vs. -35 ± 19 ml) and CI (Δ = − 0.8
(− 1.5 to − 0.5) vs. -1.5 (− 2.0 to − 1.1) l min− 1 m− 2), while SctO2 (Δ = 9 ± 5 vs. 6 ± 4%) showed more increase with
no difference in ΔSptO2 (Δ = 8 ± 7 vs. 8 ± 8%). Atropine caused higher ΔHR (13 (9 to 19) vs. 10 ± 6 bpm) and ΔCI
(0.4 ± 0.4 vs. 0.2 ± 0.3 l min− 1 m− 2) in sufentanil vs. remifentanil-based anaesthesia, with no difference in ΔMAP, ΔSV
and ΔSctO2 and ΔSptO2.
Conclusion: Induction of anaesthesia with propofol and sufentanil results in improved haemodynamic stability and
higher SctO2 compared to propofol and remifentanil in patients having CABG. Administration of atropine might be
useful to counteract or prevent the haemodynamic suppression associated with these opioids.
Trial registration: Clinicaltrials.gov on June 7, 2013 (trial ID: NCT01871935).
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Background
Balanced general anaesthesia with a combination of pro-
pofol and remifentanil, as compared to propofol with
other opioids like sufentanil, provides some beneficial
pharmacological properties, such as a fast and reliable
induction and reversal of anaesthesia, swift postoperative
recovery and avoidance of postoperative nausea and
vomiting [1, 2]. However, vasodilation and cardiac de-
pression caused by this type of anaesthesia often induces
a decrease in mean arterial pressure (MAP), heart rate
(HR) and cardiac index (CI), raising concerns on main-
taining an adequate tissue oxygenation [3–5].
Haemodynamic suppression is often observed after in-
duction of general anaesthesia with any combination of
hypnotics and opioids. Because of the distinct pharma-
codynamic differences of remifentanil compared to other
opioids such as sufentanil or fentanyl, different haemo-
dynamic side effects may occur with differential effects
on tissue oxygenation [6–8]. In addition to a strong sup-
pressive effect on the heart rate, remifentanil dose-
dependently depresses the sinus and AV node function,
and significantly prolongates the sinus node recovery
time, sino-atrial conduction time and Wenckebach cycle
length, resulting in an inhibition of both the intra-atrial
conduction and sinus node automaticity [7, 8]. This dis-
tinct effect of remifentanil on cardiac conduction might
have a particularly significant negative impact on the
cardiac index compared to sufentanil.
Perioperative maintenance of adequate tissue oxygen-
ation has been associated with less postoperative compli-
cations, such as reduction in surgical wound infections
and length of hospital stay, and is specifically important
for high-risk surgical patients, including patients sched-
uled for coronary artery bypass grafting surgery [9–11].
Beneficial effects of atropine, not only on MAP and
HR, but also on CI during propofol-remifentanil anaes-
thesia in patients undergoing non-cardiac surgery have
been reported [12]. However, this may not be equally
valid during anaesthesia with propofol combined with
other opioids, such as sufentanil, and in patients under-
going cardiac surgery. Positive inotropic agents such as
dopamine, dobutamine or ephedrine are in general pref-
erably used in cardiac surgery. However, the prominent
effect of remifentanil on the cardiac conduction suggests
that it has a direct parasympathicomimetic effect,
thereby making a beneficial effect of atropine more
likely. In these circumstances, atropine may not only
mitigate bradycardia and increase the arterial blood
pressure, but also increase CI and tissue oxygenation.
We therefore hypothesised that induction of anaesthesia
with propofol and sufentanil results in different haemo-
dynamic suppression and tissue oxygenation values com-
pared to anaesthesia with propofol and remifentanil in
calculated equipotent dosages. Also, we expected that
atropine will have different effects on the haemodynamic
suppression and tissue oxygenation in both groups.
Methods
Ethical approval for this study was provided by the Eth-
ical Committee of University Medical Center Groningen,
Groningen, The Netherlands. After registration at Clini-
calTrials.gov (Ref: NCT01871935), all patients ≥18 years
scheduled for elective off-pump performed Coronary Ar-
tery Bypass Grafting (CABG) surgery between 17 June
2013 and 1 October 2013 were assessed for eligibility for
this interventional, prospective randomised controlled
trial according to the CONSORT group statement
(Fig. 1) [13]. Patients undergoing emergency surgery or
with a contraindication for atropine administration, such
as severe aortic valve stenosis, were excluded. In
addition, morbidly obese patients (body mass index > 35
kg m− 2) were excluded, since anaesthesia with target
controlled infusion (described below) in this patient cat-
egory is not reliable [14]. There was no selection made
based on age, gender, co-morbidity or ethnic back-
ground. Following written informed consent, all included
patients were randomly assigned to the sufentanil or
remifentanil group using the sealed opaque envelope
technique. Randomisation was unblinded only after fin-
ishing the full data collection. The complete study ad-
hered to CONSORT guidelines [13].
Study protocol
Based on theoretical drug interaction pharmacodynamic
models [15], for propofol/sufentanil and propofol/remi-
fentanil, equipotent opioid targeted effect site concentra-
tions (Cet) were calculated to be 0.48 ng ml− 1 (Gepts
model) and 8 ng ml− 1 (Minto model) respectively.
Before induction of anaesthesia, adequate pre-
oxygenation of the patient’s lungs was performed via a
face mask. Anaesthesia was induced as follows: according
to randomisation, a syringe pump with sufentanil (target-
controlled infusion (TCI), targeted effect site concentra-
tion (Cet) 0.48 ngml− 1, Gepts model) or dose of remifen-
tanil (TCI Cet 8 ngml− 1, Minto model) was started,
followed in both cases by a syringe pump containing pro-
pofol (TCI Cet 2.0 μgml− 1, Schnider model) [16–18].
Doses were left unchanged throughout the study
period. Maximal reproducibility of the anaesthetic
pharmacological condition was pursued by using these
propofol and opioids effect site concentrations to obtain
a tolerance of laryngoscopy in 95% of patients as pre-
dicted by a hierarchical interaction model [3, 19, 20].
After loss of consciousness and achievement of a bispec-
tral index value between 40 and 60, rocuronium (0.6 mg
kg− 1) was administered and the patient’s trachea was
intubated. Mechanical ventilation was started in the vol-
ume control mode (tidal volume: 8 ml kg− 1) with an O2/
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air mixture (FiO2 0.4) and a positive end-expiratory pres-
sure of 5 cmH2O. The respiratory rate was adjusted to
keep end-tidal carbon dioxide partial pressure between
4.5 kPa (34 mmHg) and 5.5 kPa (42 mmHg).
If the HR dropped below 60 beats per minute (bpm),
methylatropine (1 mg) was administered intravenously.
In those cases where the patient had a baseline HR < 60
bpm prior to the induction of anaesthesia, methylatro-
pine (1 mg) was administered when HR dropped more
than 10% below the awake HR value.
If the MAP dropped below 80% of the baseline value,
without the above-mentioned indications for administra-
tion of atropine or from 3min after the administration
of atropine, other appropriate measures (e.g. fluid or
vasopressor administration) were taken.
Haemodynamic monitoring
Upon arrival in the operating theatre standard monitor-
ing equipment was connected to the patient: ECG, pulse
oximetry and non-invasive blood pressure monitoring
(Philips IntelliVue MX800, Philips, Eindhoven, The
Netherlands) and routine physiological measurements
and monitoring was started. Subsequently two large per-
ipheral intravenous cannulas and an invasive arterial
catheter were inserted for invasive blood pressure moni-
toring, as is usual practice in cardiothoracic anaesthesia.
In addition, a FloTrac sensor (Edwards Lifesciences, Ir-
vine, United States) was connected to the arterial line
and subsequently to the Vigileo monitor (Edwards Life-
sciences). The FloTrac-Vigileo system analysis the arter-
ial pressure waveform for calculation of the stroke
volume (SV) and CI [21]. Two INVOS™ Cerebral Oxim-
eter (Medtronic, Minneapolis, United States) sensors
were placed on the patients’ forehead to record cerebral
tissue oxygenation (SctO2) [22] and an InSpectra™
(Hutchinson Technology Inc., Hutchinson, United
States) probe was positioned on the thenar eminence to
measure the peripheral tissue oxygenation (SptO2) [23].
Fig. 1 CONSORT flow diagram
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Both devices rely on near-infrared spectroscopy technol-
ogy [24]. Briefly, the sensors positioned on the patient’s
skin emit light in several device-specific wavelengths
from the near infrared spectrum. Based on the ratio of
oxygenated and deoxygenated haemoglobin in the
underlying tissue, these light signals are partially
absorbed and partially reflected to the sensors [25].
Changes relative to baseline tissue oxygenation are sig-
nificantly correlated with oxygen delivery and perfusion
deficits [26].
Data registration and analysis
All data from routine physiological measurements and
from the additional study devices were recorded con-
tinuously (sampling rate of 1 Hz) on the central hospital
server using a cardiothoracic specific data management
system (Carola, University Medical Center Groningen,
Groningen, The Netherlands).
The electronic data were imported into Microsoft
Excel 2016® (Microsoft, Redmond, United States) for
synchronization and analysis. After graphical representa-
tion, absent values caused by artifacts were corrected by
interpolation during a visual inspection of the data plots.
Subsequently, we calculated the rate pressure product
(RPP) by multiplying the systolic arterial pressure and
heart rate. RPP is a surrogate measure of myocardial
oxygen uptake [27, 28].
Additionally, a 30 s running median with 15 s steps
was calculated for all studied variables. The evolution of
the absolute values and of the changes relative to base-
line was plotted from 1min before the induction of an-
aesthesia until 6 min afterwards, and from 1min before
the administration of atropine until 4 min afterwards.
This covers the time to achieve relative steady state for
all study variables.
Statistical analysis
The primary outcome measure was the change in CI
around the moment of atropine administration. Second-
ary outcome measures were the changes in MAP, SctO2
and SptO2.The sample size calculation was based on the
primary endpoint, CI. A mean difference in CI of 10%
between sufentanil and remifentanil was considered clin-
ically relevant. We expected the standard deviation to be
10% in both groups. A type I error probability of 0.05
and a power of 0.95 delivers a total sample size of 54
[29]. A supplemental 25% of patients were included in
each group to anticipate invalid data recordings and pa-
tients not meeting the criteria for atropine administra-
tion, making a total of 70 patients (35 patients in each
group).
Statistical analysis was performed in SPSS version 23
(IBM Corporation, Armonk, United States). Categorical
variables are given as number of patients and analysed
with the Chi-square test or the Fisher’s exact test. Con-
tinuous data are expressed as mean ± SD or median
(IQR), depending on the Kolmogorov-Smirnov tested
normality. Differences between groups were tested on
absolute values during the induction of anaesthesia and
during atropine administration, Time = 0min (T0), and
at the moment of steady state (after the time to peak of
propofol, sufentanil and remifentanil or atropine [30,
31], Time = 6min (T6) for the induction of anaesthesia
and Time = 4min (T4) for the administration of atro-
pine, and on relative changes (Δ = value (T6 or T4) –
value (T0)). To compare continuous variables of the dif-
ferent groups, the unpaired student t-test was used for
parametric variables, and the Mann-Whitney U test for
non-parametric variables. Comparison of the values of
the haemodynamic variables from the same group be-
tween T0 and T6 (for the induction of anaesthesia) or T4
(for the administration of atropine) was performed using
a paired t-test and Wilcoxon signed rank test for para-
metric and non-parametric variables, respectively. Two-
tailed tests were performed and statistical significance
was defined as P < 0.05 (after Bonferroni correction for
multiple comparisons) in all cases.
Results
A total of 70 patients were included in this double blind,
randomised controlled trial and subsequently allocated
to the sufentanil or remifentanil group (Fig. 1). From
these, we had to exclude 10 patients before the analysis
of the haemodynamic effects of the induction of anaes-
thesia due to deviation from the study protocol (n = 8),
cardiac arrhythmia (n = 1) or measuring equipment mal-
function (n = 1). An additional 20 patients were ex-
cluded from the analysis of the effects of atropine
administration by reason of study protocol deviation
(n = 7) and not meeting the criteria for atropine admin-
istration (n = 13). Protocol deviations comprises usage of
a different dose of hypnotics and/or opioids than de-
scribed in the protocol, additions to anaesthesia (e.g.
volatile anaesthesia) or the use of additional haemo-
dynamic support (fluid or vasopressor administration)
during the measurement periods (from 1min before in-
duction of anaesthesia or administration of atropine
until respectively 6 or 4 min thereafter). Table 1 shows
the baseline characteristics of the patients per analysis in
both groups. American Society of Anaesthesiologists
classification of Physical Health was not included in this
table, because all patients belong to American Society of
Anaesthesiologists class III. There were no significant
between-group differences for both analyses.
Haemodynamic effects after the induction of anaesthesia
The course over time of the investigated variables after
the induction of anaesthesia is shown in Figs. 2 and 3.
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Table 1 Baseline characteristics of the patients per analysis in the sufentanil and remifentanil group









Age (years) 64 ± 8 67 ± 8 66 ± 9 70 ± 7
Sex, male 23 23 18 16
Height (cm) 174 ± 10 174 ± 11 175 ± 8 175 ± 11
Weight (kg) 81 ± 16 78 ± 11 82 ± 14 83 ± 11
BMI (kg m− 2) 27 ± 4 26 ± 3 27 ± 4 27 ± 3
Medical history
Arterial hypertension 20 21 13 15
Peripheral vascular disease 4 2 4 0
Diabetes mellitus 11 7 8 5
Chronic obstructive pulmonary disease 8 8 6 4
Relevant medication
Beta blocking agents 27 29 18 18
Angiotensin receptor blockers 7 4 6 1
Angiotensin-converting enzyme inhibitors 14 19 9 13
Continuous variables are reported as mean ± SD and categorical data as numbers
Fig. 2 Mean values (thick lines) and individual patient data (thin lines) of the investigated haemodynamic variables: mean arterial pressure (MAP), heart
rate (HR), stroke volume (SV), cardiac index (CI), cerebral tissue oxygen saturation (SctO2) and peripheral tissue oxygen saturation (SptO2). Red lines
represent the sufentanil group and green lines the remifentanil group. Graphs are shown from 1min before until 6min after the induction of anaesthesia
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Table 2 shows all haemodynamic data. Both in the
sufentanil group and in the remifentanil group MAP,
HR, SV, CI, and RPP were significantly decreased 6 min
after induction (T6) as compared to baseline (T0). In
contrast, SctO2 and SptO2 were significantly increased
between T0 and T6. Between-groups comparison (sufen-
tanil vs. remifentanil) of the mean relative changes
showed less decrease in: MAP (Δ = − 23 ± 13 vs. -36 ± 13
mmHg; P < 0.001), HR (Δ = − 5 ± 7 vs. -10 ± 10 bpm;
P = 0.025), SV (Δ = − 23 ± 18 vs. -35 ± 19ml; P = 0.017),
CI (Δ = − 0.8 (− 1.5 to − 0.5) vs. -1.5 (− 2.0 to − 1.1) l
min− 1 m− 2; P = 0.002) and RPP (Δ = − 3077 ± 2010 vs.
-5002 ± 2369 mmHg bpm; P = 0.001) and a larger in-
crease in SctO2 (Δ = 9 ± 5 vs. 6 ± 4%; P = 0.040) in the
sufentanil group compared to the remifentanil group.
The mean relative changes in SptO2 (Δ = 8 ± 7 vs. 8 ±
8%; P = 0.641) did not differ significantly between
groups.
Haemodynamic effects after the administration of
atropine
Seventy-seven percent of the patients in the sufen-
tanil group and 80 % in the remifentanil group re-
ceived atropine. The course of the investigated
Fig. 3 Mean relative changes of the investigated haemodynamic variables during the induction of anaesthesia (from 1min before until 6 min
after). Mean arterial pressure (ΔMAP), heart rate (ΔHR), stroke volume (ΔSV), cardiac index (ΔCI), cerebral tissue oxygen saturation (ΔSctO2) and
peripheral tissue oxygen saturation (ΔSptO2)
Poterman et al. BMC Anesthesiology          (2020) 20:258 Page 6 of 12
variables after the administration of atropine is
shown in Figs. 4 and 5. Table 3 shows all haemo-
dynamic data. In both groups HR, CI, and RPP
were significantly increased compared to baseline
(T0). SctO2 significantly decreased compared to
baseline (T0) in the remifentanil group, but not in
the sufentanil group. Between-groups comparison
(sufentanil vs. remifentanil) of the mean relative
changes showed more increase in: HR (Δ = 13 (9 to
19) vs. 9 (6 to 14) bpm; P = 0.016), CI (Δ = 0.4 ± 0.4
vs. 0.2 ± 0.3 l min− 1 m− 2; P = 0.023) and RPP (Δ =
1584 ± 1413 vs. 810 ± 917 mmHg bpm; P = 0.027) in
the sufentanil group after atropine administration.
MAP, SV and tissue oxygenation values were equal
in both groups during measurements. Maximum
RPP during the measurement period was 12,556
mmHg bpm.
Discussion
This prospective double-blind randomised controlled
trial demonstrates that induction of anaesthesia with
propofol and sufentanil results in less haemodynamic
suppression than induction of anaesthesia with pro-
pofol and a calculated equivalent dosage of remifen-
tanil, combined with more pronounced positive
effect on SctO2 values in the sufentanil group. Ad-
ministration of atropine reversed bradycardia and
thus maintained haemodynamics and tissue oxygen-
ation with no (clinically) relevant between-groups
differences.
After the induction of anaesthesia with comparable
doses of opioids, remifentanil did not only cause a
more evident decrease in HR, but also in SV. Remi-
fentanil is well known for its direct bradycardic ef-
fects, especially compared to other opioids, but not
for the negative effect on SV [6, 12]. As a result of a
decreased HR, an increase in SV would typically be
expected, due to a longer diastolic filling time. This
more pronounced decrease in SV in the remifentanil
group might be explained by a stronger direct nega-
tive inotropic effect of remifentanil, different changes
in cardiac preload, or pharmacokinetic differences be-
tween both opioids. A larger decrease in HR and SV
in the remifentanil group however resulted in a much
larger decrease in MAP and CI, and thereby overall
more haemodynamic suppression than in the sufenta-
nil group. Furthermore, patients in the remifentanil
group demonstrated lower SctO2 values. During in-
duction of anaesthesia, a raised inspired oxygen frac-
tion combined with general vasodilation results in an
overall increased tissue oxygenation [12]. Despite this,
the more pronounced haemodynamic suppression in
the remifentanil group led to lower SctO2 values than
in the sufentanil group. This difference could only be
demonstrated in terms of absolute SptO2 values, but
not in the mean relative values. Also, anaesthesia with
more stable haemodynamics, like with sufentanil, will
clinically lead to less use of vasoactive medication,
e.g. norepinephrine, and thereby less additional
haemodynamic suppression and possibly higher tissue
oxygenation values [5].
Table 2 Haemodynamic data in the sufentanil and remifentanil group after the induction of anaesthesia
T0 T6 Δ P - value*
MAP (mmHg) Sufentanil 101 ± 15 78 ± 15 − 23 ± 13 < 0.001
Remifentanil 100 ± 11 65 ± 11 −36 ± 13 < 0.001
HR (bpm) Sufentanil 64 ± 9 59 ± 8 −5 ± 7 < 0.001
Remifentanil 68 ± 14 58 ± 12 − 10 ± 10 0.001
SV (ml) Sufentanil 101 ± 25 78 ± 21 − 23 ± 18 < 0.001
Remifentanil 97 ± 21 62 ± 21 − 35 ± 19 < 0.001
CI (l min− 1 m− 2) Sufentanil 3.2 (2.7 to 3.9) 2.3 (1.8 to 2.8) −0.8 (− 1.5 to − 0.5) < 0.001
Remifentanil 3.5 (2.7 to 3.9) 1.8 (1.4 to 2.3) −1.5 (− 2.0 to − 1.1) < 0.001
RPP (mmHg bpm) Sufentanil 10,004 ± 2200 6928 ± 1893 −3077 ± 2010 < 0.001
Remifentanil 10,730 ± 2444 5728 ± 1845 −5002 ± 2369 < 0.001
SctO2 (%) Sufentanil 68 ± 8 77 ± 7 9 ± 5 < 0.001
Remifentanil 67 ± 7 73 ± 8 6 ± 4 < 0.001
SptO2 (%) Sufentanil 77 ± 10 85 ± 7 8 ± 7 < 0.001
Remifentanil 72 ± 11 80 ± 9 8 ± 8 < 0.001
Variables are reported as mean ± SD or median (IQR), according to data distribution
Δ: value (T6) – value (T0); MAP Mean Arterial Pressure; HR Heart Rate; SV Stroke Volume; CO Cardiac Output; SctO2 Cerebral Tissue Oxygen Saturation; SptO2
Peripheral Tissue Oxygen Saturation
* (T6 vs. T0), paired t-test or Wilcoxon signed rank test
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Contrary to our hypothesis, administration of atro-
pine did not result in better attenuation of the
haemodynamic suppression caused by remifentanil or
higher tissue oxygenation values compared to anaes-
thesia with sufentanil. Although only demonstrated
in absolute values, the sufentanil group showed
higher HR and remarkably higher CI values than the
remifentanil group. Compared to other opioids,
remifentanil evokes a dose dependent prolongation
of the cardiac conduction times (by influencing the
sinus and atrioventricular node and intra-atrial
conduction), inhibition of sinoatrial automaticity and
vagally mediated inotropic effects [7, 32]. In accord-
ance with previous observations, we expected more
distinct positive effects of atropine on the haemo-
dynamic variables and tissue oxygenation during
remifentanil based anaesthesia [12]. However, in our
previous study from non-cardiac surgery, none of
the patients were on beta-blocking agents, as op-
posed to the 90% in both of the groups of the
current study, which exclusively included patients
with ischemic heart disease. Our results show that,
not only in patients with extreme bradycardia, atro-
pine significantly improves cardiac index and blood
pressure in many cases, which may in clinical prac-
tice often obviate the necessity for further interven-
tions such as starting a syringe pump with
vasopressive medication. Unfortunately, the method-
ology of this study did not permit to show any out-
come improvement. This was, however not the
purpose of the study; the objective was to demon-
strate that atropine (especially in remifentanil-based
anaesthesia) can induce a significant increase in
blood pressure and cardiac output (CO), allegedly by
counteracting the parasympathicomimetic effects of
the opiates.
Administering atropine in patients undergoing
CABG could lead to certain objections, since all of
the patients suffer from coronary artery disease. An
unwanted increase in HR can result in an increase
Fig. 4 Mean values (thick lines) and individual patient data (thin lines) of the investigated haemodynamic variables: mean arterial pressure (MAP),
heart rate (HR), stroke volume (SV), cardiac index (CI), cerebral tissue oxygen saturation (SctO2) and peripheral tissue oxygen saturation (SptO2).
Red lines represent the sufentanil group and green lines the remifentanil group. Graphs are shown from 1min before until 4 min after the
administration of atropine
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in the RPP, which is a measure of the internal work-
load of the heart and a direct indication of the myo-
cardial oxygen demand. However, maximum RPP
during the measurement period after the atropine
administration was 12,556 mmHg bpm. This value
corresponds with a low internal workload and thus
indicates a low myocardial oxygen consumption,
probably owing to the patients being under anaes-
thesia [26, 27]. Also, none of the closely monitored
patients showed signs of cardiac ischemia. Other
contraindications for the use of atropine, like severe
aortic valve stenosis, were covered in the exclusion
criteria.
There are certain study limitations that need to be
addressed. Firstly, equipotent doses of the used opi-
ates are so far not reliably determined in the litera-
ture and consequently, we were limited to calculated
equipotent doses based on interaction models. Al-
though we consider that these values sufficiently reli-
ably represent clinical reality, different observations
may occur depending on opiate doses. Secondly, we
used the FloTrac-Vigileo system for the recording of
the course of the SV and CI after the induction of
anaesthesia and after atropine administration. These
variables are calculated via arterial pressure wave-
form analysis, which leads to a certain inevitable
Fig. 5 Mean relative changes of the investigated haemodynamic variables during the administration of atropine (from 1min before until 4 min
after). Mean arterial pressure (ΔMAP), heart rate (ΔHR), stroke volume (ΔSV), cardiac index (ΔCI), cerebral tissue oxygen saturation (ΔSctO2) and
peripheral tissue oxygen saturation (ΔSptO2)
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inaccuracy. Previous studies show varying outcomes
in agreement and trending ability when FloTrac-
Vigileo calculated CO is compared with CO derived
from the widely accepted reference method, i.e. ther-
modilution [19]. Consequently, to minimize measure-
ment bias, we used relative (Δ) values instead of
absolute values for the comparisons [33, 34].
Also, tissue oxygenation values based on near-infrared
spectroscopy and measured during haemodynamic
changes, like after induction of anaesthesia, should be
interpreted with caution. Reduced skin blood flow and
oxygenation, caused by vasoconstrictive medication,
hyperventilation and hypoxia, has shown to influence
measurement values to some extent [35, 36]. These results
however could not be reproduced when norepinephrine
was administered to treat postspinal hypotension [37].
Moreover, reduction in SctO2 after vasoconstrictive medi-
cation has previously been correlated with a decrease in
oxygen saturation measured at the level of the jugular
venous bulb [38]. As a consequence, we have to assume
that the changes in SctO2 and SptO2 we demonstrated are
at least partially caused by changes in skin perfusion.
Nevertheless, our data showed a much more evident
increase in tissue oxygenation after induction of anaesthesia
(6–9% increase), than reported as influence by a
change in skin oxygen saturation (2–3% change) [35, 36].
Lastly, for the analysis of the effects of atropine on
haemodynamics and tissue oxygenation we used a fixed
dose of 1 mg. This could partially account for the (inter-
individual) differences in the response of haemodynamic
variables to the administration of atropine.
Conclusions
Induction of anaesthesia with propofol and sufentanil re-
sults in improved haemodynamic stability and higher
cerebral tissue oxygenation compared to propofol and
remifentanil in CABG patients. Administration of
atropine might be useful to counteract or prevent the
bradycardic action and thus haemodynamic suppression
associated with these opioids.
Abbreviations
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Table 3 Haemodynamic data in the sufentanil and remifentanil group after atropine administration
T0 T4 Δ P - value*
MAP (mmHg) Sufentanil 69 (63 to 81) 72 (67 to 80) 4 (−2 to 9) 0.101
Remifentanil 67 (56 to 78) 64 (57 to 77) 1 (−2 to 6) 0.942
HR (bpm) Sufentanil 57 (49 to 59) 70 (63 to 74) 13 (9 to 19) < 0.001
Remifentanil 53 (50 to 58) 64 (56 to 70) 9 (6 to 14) < 0.001
SV (ml) Sufentanil 69 ± 17 67 ± 23 −3 ± 10 0.253
Remifentanil 63 ± 14 59 ± 12 −4 ± 11 0.110
CI (l min−1 m−2) Sufentanil 2.0 ± 0.5 2.3 ± 0.8 0.4 ± 0.4 0.001
Remifentanil 1.7 ± 0.3 1.9 ± 0.4 0.2 ± 0.3 0.032
RPP (mmHg bpm) Sufentanil 5590 ± 918 7173 ± 1589 1584 ± 1413 < 0.001
Remifentanil 5204 ± 1053 6014 ± 1590 810 ± 917 0.001
SctO2 (%) Sufentanil 73 (68 to 79) 73 (65 to 78) −2 (−3 to 1) 0.120
Remifentanil 72 (66 to 75) 69 (65 to 74) -2 (−2 to −1) 0.005
SptO2 (%) Sufentanil 88 (81 to 91) 88 (83 to 91) 1 (−1 to 2) 0.582
Remifentanil 83 (78 to 86) 81 (77 to 86) 0 (−1 to 0) 0.471
Variables are reported as mean ± SD or median (IQR), according to data distribution
Δ: value (T4) – value (T0); MAP Mean Arterial Pressure; HR Heart Rate; SV Stroke Volume; CO Cardiac Output; SctO2 Cerebral Tissue Oxygen Saturation; SptO2
Peripheral Tissue Oxygen Saturation
* (T4 vs. T0), paired t-test or Wilcoxon signed rank test
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